Prime Medicine vs Entrada Therapeutics
Entrada Therapeutics is the larger business, with $25.4m of revenue in fiscal 2025 against $4.6m for Prime Medicine (5.5 times as much). Prime Medicine grew faster (55.3% against -87.9%). Entrada Therapeutics kept more of each dollar of sales as profit: a net margin of -565.5% against -4342.4%. Prime Medicine carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Prime MedicinePRME, 2025 | Entrada TherapeuticsTRDA, 2025 |
|---|---|---|
| Revenue | $4.6m | $25.4m |
| Revenue growth | 55.3% | -87.9% |
| Net income | −$201m | −$144m |
| Operating margin | -4498.1% | -621.1% |
| Net margin | -4342.4% | -565.5% |
| Return on equity | -146.8% | -39.1% |
| Free cash flow | −$167m | −$130m |
| Cash | $63.0m | $90.4m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 146 | 152 |
| Market value | $807m | $185m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 17 buys, 44 sales |